On the assumption that the federal prohibition on cannabis ends by 2020, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to 25 billion U.S. dollars in 2025 and be worth 50 billion U.S. dollars in 2029.

The therapeutic potential of cannabinoids Cannabis – also known as marijuana – contains active ingredients called cannabinoids. The second-most abundant cannabinoid found in cannabis is cannabidiol (CBD), a chemical substance that is considered to have a broad range of medical benefits. Clinical trials to test the effects of cannabis-based drugs are ongoing, but potential treatments have been identified for cancer pain, glaucoma, and epilepsy. Annual sales of CBD products in the United States were expected to generate around three million U.S. dollars in 2019, with sales from the state of California contributing a 25 percent share.

Medical marijuana laws by state In 1996, California became the first state in the United States to allow the medical use of cannabis. As of 2018, the market for medical marijuana in the United States had grown to 33 states and Washington D.C. – the state of Oklahoma had the fastest-growing medical marijuana market in the country. More states may loosen their marijuana laws over the next few years, but for the time being, cannabis remains federally illegal in the United States.

The North America Cannabinoid Drugs market report offers a thorough competitive analysis, mapping key players’ strategies, market share, and business models. It provides insights into competitor dynamics, helping companies align their strategies with the current market landscape and future trends.

Discover the booming cannabis drug market: Explore its projected $15 billion valuation by 2033, key drivers, regional trends, and leading companies like GW Pharmaceuticals and AbbVie. Learn about market restraints and future growth potential.

Cannabis pharmaceuticals market worth at USD 3.17 Billion in 2024, is expected to surpass USD 34.92 Billion by 2034, CAGR of 24.5% from 2025 to 2034.

Cannabinoid-based Pharmaceuticals Market Outlook

According to our latest research, the global cannabinoid-based pharmaceuticals market size reached USD 2.6 billion in 2024, reflecting a robust growth trajectory driven by an increasing acceptance of cannabinoids in mainstream medicine. The market is anticipated to expand at a CAGR of 15.8% from 2025 to 2033, reaching an estimated USD 9.2 billion by 2033. This accelerated growth is primarily attributed to the rising prevalence of chronic diseases, progressive legislative reforms, and the expanding pipeline of cannabinoid-derived therapeutics.

The primary growth factor for the cannabinoid-based pharmaceuticals market is the increasing recognition of cannabinoids’ therapeutic benefits in the management of complex medical conditions. As clinical evidence supporting the efficacy of cannabinoids in treating ailments such as epilepsy, chronic pain, and multiple sclerosis continues to mount, healthcare practitioners and patients alike are showing greater willingness to adopt these novel pharmacological solutions. Furthermore, the approval of landmark drugs like Epidiolex and Sativex by regulatory bodies such as the FDA and EMA has bolstered confidence in cannabinoid-based therapies, paving the way for further research and development in this space. The growing awareness among patients regarding alternative therapies, coupled with the limitations of conventional pharmaceuticals in addressing certain refractory conditions, is catalyzing the shift towards cannabinoid-based medicines.

Another significant driver is the progressive legalization and decriminalization of medical cannabis across key markets, particularly in North America and Europe. Governments are increasingly acknowledging the therapeutic potential of cannabinoids, leading to favorable regulatory frameworks that facilitate clinical trials, product approvals, and commercialization. This regulatory momentum is encouraging pharmaceutical companies to invest in cannabinoid research, expand their product portfolios, and collaborate with academic institutions for drug discovery. Additionally, the growing acceptance of medical cannabis is reducing stigma, enabling broader patient access, and fostering partnerships between industry stakeholders and healthcare providers. These developments are collectively enhancing the growth prospects of the cannabinoid-based pharmaceuticals market.

Technological advancements in drug formulation and delivery systems are also contributing to the expansion of this market. Innovations such as nanoemulsions, transdermal patches, and controlled-release formulations are improving the bioavailability and therapeutic efficacy of cannabinoid-based drugs. Pharmaceutical companies are leveraging advanced manufacturing technologies to develop standardized, high-quality products that meet stringent regulatory requirements. This focus on quality and consistency is crucial for gaining the trust of healthcare professionals and patients, thereby driving market adoption. Moreover, ongoing research into novel cannabinoids and their synergistic effects is likely to yield new therapeutic candidates, further diversifying the market landscape.

Regionally, North America continues to dominate the cannabinoid-based pharmaceuticals market, accounting for over 45% of the global revenue in 2024. The region’s leadership is underpinned by a well-established healthcare infrastructure, progressive regulatory policies, and a high prevalence of target diseases. Europe is also emerging as a significant market, supported by increasing clinical research activities and a growing number of product approvals. Meanwhile, Asia Pacific is witnessing rapid growth, driven by rising healthcare expenditure, expanding patient populations, and increasing awareness of cannabinoid-based therapies. Latin America and the Middle East & Africa, though relatively nascent markets, are expected to exhibit accelerated growth rates as regulatory landscapes evolve and patient access improves.

Product Type Analysis

The report offers Cannabinoid Drugs Market Dynamics, Comprises Industry development drivers, challenges, opportunities, threats and limitations. A report also incorporates Cost Trend of products, Mergers & Acquisitions, Expansion, Crucial Suppliers of products, Concentration Rate of Steel Coupling Economy. Global Cannabinoid Drugs Market Research Report covers Market Effect Factors investigation chiefly included Technology Progress, Consumer Requires Trend, External Environmental Change.

The global cannabis drug market was valued at $12 billion in 2020, and is projected to reach $40 billion by 2028, exhibiting a CAGR of 16.5% during the forecast period. The market is primarily driven by the growing legalization of cannabis for medicinal and recreational purposes, as well as increasing research and development on its therapeutic benefits. Additionally, the rising prevalence of chronic diseases such as pain, anxiety, and insomnia is contributing to the market growth. North America is the largest regional market for cannabis drugs, followed by Europe and Asia Pacific. The United States holds a significant share of the market in North America due to the legalization of recreational cannabis in several states. In Europe, Germany and the United Kingdom are the key markets, driven by the growing acceptance of medical cannabis. In Asia Pacific, China and India are the most promising markets, with increasing government support for medical cannabis and a large patient population.

Snapshot img

Cannabinoids Market Size 2024-2028

The cannabinoids market size is forecast to increase by USD 88.4 billion at a CAGR of 30.41% between 2023 and 2028.

The market is experiencing significant growth due to the increasing recognition of cannabinoids' therapeutic potential in managing various health conditions. Key drivers include the legalization of medicinal cannabinoids and the launch of educational programs to raise awareness of their benefits. However, the market also faces challenges, such as the potential side effects associated with inappropriate use. Cannabinoids have shown promise in addressing inflammation, insomnia, cancer-related symptoms, and chronic pain. The immunological system and central nervous system are the primary targets for these compounds. As the use of cannabinoids, including marijuana and prescription drugs, becomes more widespread, it is crucial to understand their effects and proper application to maximize their benefits and minimize risks. The market's growth is expected to continue as research uncovers new applications and regulatory frameworks evolve to support their use.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

The market is witnessing significant growth due to the increasing awareness and acceptance of cannabis-derived products for various health conditions. The market encompasses a range of products, including body lotions, oils, capsules, and vaping items, derived from the cannabis sativa plant, specifically hemp, and medical cannabis. Cannabinoids are chemical compounds found in the cannabis sativa plant. The most prominent cannabinoids include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabivarin (THCV). Among these, CBD has gained significant attention due to its potential therapeutic benefits.
In addition, anxiety, seizures, muscle disorders, Parkinson's disease, chronic noncancer pain, cancer patients, neuropathy, vomiting, appetite, weight loss, and cancer progression are some of the conditions for which cannabinoids are being explored as potential treatments. The market is expected to continue its growth trajectory due to the increasing acceptance and legalization of medical cannabis and the growing body of scientific evidence supporting the therapeutic benefits of these compounds. However, it is essential to note that the regulatory landscape for these products is evolving, and it is crucial for companies to stay informed of the latest regulations and guidelines. In summary, the market in North America is experiencing steady growth due to the increasing demand for natural alternatives to synthetic products for managing various health conditions.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Application

  Medical
  Non-medical


Channel

  Retail pharmacies
  Online stores
  Hospital


Geography

  North America

    Canada
    US


  Europe

    Germany


  APAC



  South America



  Middle East and Africa

By Application Insights

The medical segment is estimated to witness significant growth during the forecast period.

Medical cannabinoids derived from the Cannabis sativa plant, including Cannabidiol (CBD) and Tetrahydrocannabinol (THC), have emerged as potential alternatives to conventional pain management medications in the US. These compounds have shown efficacy in alleviating chronic non-cancer pain, particularly pain caused by nerve damage and inflammation. The increasing prevalence of chronic pain among adults in the country is a significant factor driving the growth of the market. Furthermore, medical cannabis testing and legalization in several states are fueling market expansion. In addition to pain relief, cannabinoids have demonstrated potential in treating conditions causing severe nausea, such as Crohn's disease, acute gastritis, hypoglycemia, panic disorder, and arachnoiditis.

Get a glance at the market report of share of various segments Request Free Sample

The medical segment was valued at USD 10.30 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 64% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions Request Free Sample

In North America, the legalization of cannabinoids for medical use in the United States and Canada is fueling market expansion. Notable companies providing cannabinoids in this region mimic the cannabinoid compounds naturally produced

The expected 4.7% CAGR from 2025 to 2035 indicates a rising trend in cannabis addiction treatment generalisedIndice, both research-specific and healthcare-focused. Integration of Mental Health Services with Addiction Treatment Programs to Augment Patient Outcomes and Drive Market Expansion.

Key Market Metrics

Country-wise Outlook

Competitive Outlook

Cannabinoids Market Outlook

According to our latest research, the global cannabinoids market size in 2024 stands at USD 22.3 billion, driven by increasing acceptance of medical cannabis, ongoing legalization efforts, and expanding applications in health, wellness, and personal care. The market is projected to grow at a robust CAGR of 17.2% over the forecast period, reaching an estimated USD 67.2 billion by 2033. This substantial growth is propelled by rising consumer awareness, evolving regulatory frameworks, and surging demand for cannabinoid-infused products across various industries, according to our comprehensive market analysis.

One of the primary growth factors for the cannabinoids market is the accelerating pace of medical cannabis legalization in key global markets. Countries such as the United States, Canada, Germany, and Australia are at the forefront, enacting favorable policies that enable the use of cannabinoids, particularly CBD (Cannabidiol) and THC (Tetrahydrocannabinol), in the treatment of chronic pain, neurological disorders, and cancer-related symptoms. This legislative shift not only enhances patient access to cannabinoid-based therapies but also encourages pharmaceutical innovation and clinical research. As a result, pharmaceutical companies are increasingly investing in the development of cannabinoid-derived drugs, further propelling market growth and expanding the therapeutic landscape for cannabinoids.

Another significant driver is the growing adoption of cannabinoids in the food and beverages, nutraceuticals, and personal care sectors. Consumers are increasingly seeking natural remedies and functional ingredients that promote wellness, stress relief, and improved sleep quality. This trend has led to a surge in demand for CBD-infused edibles, beverages, topical creams, and supplements, particularly in North America and Europe. The proliferation of online retail platforms and specialty stores has further democratized access to these products, making them widely available to a diverse consumer base. As regulatory clarity improves and product quality standards are enforced, consumer confidence in cannabinoid-based products is expected to rise, fueling market expansion.

Technological advancements in extraction and synthesis methods are also shaping the cannabinoids market. The emergence of synthetic cannabinoids and improved extraction techniques for hemp and marijuana-derived cannabinoids have enabled manufacturers to achieve higher purity, consistency, and scalability. These innovations not only facilitate the development of novel cannabinoid formulations but also allow for the customization of products to meet specific therapeutic or recreational needs. Furthermore, the increasing investment in research and development by both established companies and startups is driving the discovery of minor cannabinoids such as CBG (Cannabigerol) and CBN (Cannabinol), which hold promising potential for new applications in pharmaceuticals and wellness products.

Cannabis has played a pivotal role in the evolution of the cannabinoids market, particularly as its medical applications gain widespread recognition. The plant's compounds, such as CBD and THC, are increasingly being studied for their potential to treat a variety of health conditions, including chronic pain and neurological disorders. As more countries move towards legalizing cannabis for medical use, the potential for cannabis to transform healthcare practices becomes more evident. This shift not only opens up new avenues for research but also encourages the development of innovative cannabis-based therapies that could redefine patient care standards globally.

Regionally, North America continues to dominate the cannabinoids market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The United States leads in terms of revenue, product innovation, and regulatory momentum, while Canada remains a key player in both medical and recreational cannabis. Europe is witnessing rapid growth due to increasing legalization and investments in cannabinoid research, especially in Germany and the United Kingdom. Meanwhile, Asia Pacific is emerging as a lucrative market, driven by rising consumer a

The global Cannabis Pharmaceuticals market is poised for substantial expansion, projected to reach an estimated market size of approximately $1319 million by 2025. This robust growth is underpinned by a compelling Compound Annual Growth Rate (CAGR) of 13.8%, signaling a dynamic and rapidly evolving industry. The primary drivers fueling this expansion include the increasing acceptance and legalization of cannabis for medicinal purposes across various regions, coupled with a growing body of scientific research validating its therapeutic benefits. Furthermore, a surge in investment within the cannabis pharmaceutical sector, driven by pharmaceutical companies and venture capitalists alike, is fostering innovation and the development of novel cannabinoid-based treatments for a wide range of ailments. The escalating prevalence of chronic conditions, such as pain management, neurological disorders, and certain forms of epilepsy, is also contributing significantly to the demand for these specialized pharmaceutical products. The market's segmentation reveals a diverse landscape. In terms of application, pharmacies and hospitals are expected to be the leading segments, reflecting the growing integration of cannabis-based medications into mainstream healthcare. However, the "Others" category, which could encompass research institutions and specialized clinics, also holds significant potential. On the product type front, sprays, capsules, and tablets are anticipated to dominate, offering convenient and precise dosing for patients. Key players like Cronos Group, Jazz Pharmaceuticals, Tilray Brands, Inc., and Canopy Growth are at the forefront, driving market advancements through strategic partnerships, product development, and market penetration efforts. Geographically, North America, particularly the United States and Canada, is expected to lead the market due to progressive regulatory frameworks and a well-established cannabis ecosystem. Europe is also a rapidly growing region, with countries like the United Kingdom and Germany showing considerable promise. This report provides an in-depth analysis of the global Cannabis Pharmaceuticals market, offering critical insights into its growth trajectory, key players, and emerging trends. Spanning a study period from 2019 to 2033, with a base year of 2025, the report delves into historical data from 2019-2024 and forecasts market dynamics for the period 2025-2033. We utilize a robust methodology to deliver granular data, with key values presented in millions of units for unparalleled clarity.

The global medicinal grade cannabis market is experiencing robust growth, driven by increasing legalization and acceptance of cannabis for therapeutic purposes, coupled with advancements in research and development leading to improved formulations and delivery methods. The market, estimated at $15 billion in 2025, is projected to witness a Compound Annual Growth Rate (CAGR) of 18% from 2025 to 2033, reaching an estimated value of $60 billion by 2033. This expansion is fueled by several key drivers, including rising prevalence of chronic pain, anxiety, and other conditions effectively treated with cannabinoids, as well as growing physician and patient awareness of cannabis' therapeutic benefits. The increasing availability of various cannabis-based medications, including dronabinol, nabilone, nabiximols, and cannabidiol (CBD), across different channels like hospitals, clinics, and pharmacies further contributes to market growth. Despite regulatory hurdles in certain regions and concerns regarding potential side effects, the overall market trajectory remains positive, reflecting a growing global shift toward the acceptance and integration of medicinal cannabis into mainstream healthcare systems. The market segmentation reveals a significant demand across diverse applications and formulations. Dronabinol, nabilone, and nabiximols dominate the product landscape, while CBD is rapidly gaining traction due to its broad therapeutic potential and lack of psychoactive effects. Geographically, North America currently leads the market, largely due to early legalization efforts and a robust regulatory framework in countries like the United States and Canada. However, substantial growth is anticipated in Europe and the Asia-Pacific region, as legalization efforts expand and consumer awareness increases. Key players, including Ultra Health, Mammoth Farms, and Canopy Growth, are actively shaping the market through product innovation, strategic partnerships, and expansion into new geographical regions. Despite competitive pressures, the market presents substantial opportunities for companies that can effectively navigate the evolving regulatory landscape and meet the growing demand for high-quality, safe, and effective medicinal cannabis products. This report provides an in-depth analysis of the burgeoning medicinal grade cannabis market, projected to reach $50 billion by 2030. It examines market dynamics, key players, emerging trends, and future growth prospects, focusing on crucial aspects such as product concentration, regulatory impact, and end-user adoption. This comprehensive study is essential for investors, industry stakeholders, and researchers seeking to navigate this rapidly evolving landscape.

The Medical Marijuana Market Report is Segmented by Formulation Type (Capsules, Oils, and More), Cannabinoid Composition (THC-Dominant, and More), Route of Administration (Oral, Inhalation, Sublingual, and More), Application (Chronic Pain, Arthritis, Migraine, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

The Cannabis Pharmaceuticals Market Share size and share are expected to exceed USD 357.96 billion by 2034, with a compound annual growth rate (CAGR) of 52.4% during the forecast period

The global cannabis pharmaceuticals market is booming, projected to reach $3.65 billion by 2033 at a CAGR of 13.8%. Discover key trends, market drivers, and leading companies shaping this rapidly expanding sector, including insights into regional market shares and product segmentation (sprays, capsules, tablets).

The global market for cannabis-based medicines is experiencing robust growth, projected to reach a substantial size in the coming years. While the exact market size in 2025 is not provided, considering a 5% CAGR from a hypothetical 2019 market size of $5 billion (a reasonable estimate given the industry's trajectory), the market value could be estimated at approximately $6.5 billion by 2025. This continued expansion, with a projected 5% CAGR through 2033, demonstrates the significant potential of this sector. Key drivers include increasing legalization and acceptance of medical cannabis, growing research into its therapeutic applications, and a rising prevalence of chronic conditions like pain and epilepsy, where cannabis-based therapies are showing promising results. Emerging trends involve the development of innovative delivery methods, such as sublingual sprays and transdermal patches, and the advancement of cannabinoid-based pharmaceuticals with precise dosages and improved efficacy. However, regulatory hurdles, concerns regarding safety and efficacy in certain patient populations, and inconsistent regulatory frameworks across different regions present significant challenges to market growth. Despite these restraints, the market is segmented by various factors, including cannabinoid type (CBD, THC, etc.), administration route, and therapeutic application. Leading companies like GW Pharmaceuticals, INSYS Therapeutics, and others are actively involved in research and development, aiming to bring more effective and safer cannabis-based medications to the market. This increased investment and competition are further driving innovation and expanding the market's potential. The geographical distribution is likely varied, with North America and Europe currently representing significant shares but emerging markets in other regions also contributing to the market's overall expansion in the coming years.

Overview

New York, NY – Aug 29, 2025 – The Global Medical Marijuana Market size is expected to be worth around USD 30 Billion by 2032 from USD 16.0 Billion in 2024, growing at a CAGR of 8.3% during the forecast period from 2025 to 2032.

The medical marijuana market is experiencing significant growth as increasing legalization and acceptance drive widespread adoption across various regions. The therapeutic use of cannabis has been recognized for its effectiveness in managing chronic pain, epilepsy, multiple sclerosis, and chemotherapy-induced side effects, thereby expanding its role within mainstream healthcare.

The global industry has witnessed rising investment from pharmaceutical companies, healthcare providers, and research institutions, which is strengthening clinical studies and improving product formulations. Technological advancements in cultivation, extraction, and product delivery methods are enhancing quality, safety, and accessibility. Furthermore, the demand for natural alternatives to synthetic drugs is encouraging patients and practitioners to adopt medical marijuana as a viable treatment option.

Government reforms and evolving regulatory frameworks in North America, Europe, and parts of Asia-Pacific are fostering a favorable environment for market expansion. Countries such as the United States, Canada, Germany, and Australia are spearheading policy changes that support medical cannabis programs.

According to industry projections, the global medical marijuana market is expected to witness substantial growth in the coming years, driven by increasing patient awareness and physician prescriptions. While regulatory complexities remain a challenge, the trajectory indicates a robust future for this sector. Medical marijuana is positioned to transform patient care by offering safe, effective, and accessible therapeutic solutions. As acceptance broadens, the industry is set to play a critical role in the future of global healthcare.
https://sp-ao.shortpixel.ai/client/to_auto,q_lossy,ret_img,w_1216,h_841/https://market.us/wp-content/uploads/2023/02/global-medical-marijuana-market-1-1.jpg" alt="global medical marijuana market (1)" width="800" height="500">

The global cannabinoid-based antitumor drug market is poised for significant growth, exhibiting a Compound Annual Growth Rate (CAGR) of 5% from 2025 to 2033. While the exact market size in 2025 is unavailable, considering a conservative estimate based on market trends and the presence of established players like GW Pharmaceuticals and Valeant Pharmaceuticals, along with emerging companies like Cannabics Inc. and Tikun Olam, a reasonable starting point for the 2025 market size would be approximately $500 million. This reflects a market already gaining traction due to the increasing research and development efforts focused on the therapeutic potential of cannabinoids in cancer treatment. The market's expansion is driven by several factors, including growing awareness of cannabinoids' potential anti-cancer properties, increasing prevalence of various cancers globally, supportive regulatory frameworks in certain regions, and advancements in drug delivery systems for improved efficacy and patient compliance. This growth trajectory is further fueled by ongoing clinical trials evaluating the effectiveness of cannabinoid-based therapies across different cancer types and stages. The market segmentation, encompassing various delivery forms (chewing medicine, lozenges, others) and application areas (clinics, hospitals, others), offers multiple avenues for market penetration. While challenges such as stringent regulatory requirements, concerns regarding potential side effects, and the need for further clinical validation remain, the overall market outlook remains positive. The strategic investments and partnerships undertaken by pharmaceutical companies indicate a growing confidence in the long-term prospects of cannabinoid-based antitumor drugs. Further regional analysis, factoring in differences in regulatory landscape and healthcare infrastructure across North America, Europe, Asia Pacific, and other regions will provide a more granular understanding of market potential and opportunities within this rapidly evolving therapeutic area.

Discover Market Research Intellect's Cannabinoid Derived Pharmaceutical Market Report, worth USD 6.9 billion in 2024 and projected to hit USD 18.6 billion by 2033, registering a CAGR of 15.1% between 2026 and 2033.Gain in-depth knowledge of emerging trends, growth drivers, and leading companies.

Explore the booming Delta-9-Tetrahydrocannabinol (THC) market, driven by pharmaceutical innovation and legalization. Discover key drivers, restraints, and regional growth for THC market trends from 2019-2033.